Updated on 9 April 2013
There are several other Indian companies who have collaborated with firms from the US. For instance, Jubilant Biosys, a collaborator for pharma and biotech companies offering end-to-end discovery R&D services, on February 21, 2012, entered into drug discovery collaboration with Mnemosyne Pharmaceutical to identify preclinical candidates in the area of neuropsychiatric diseases. The partnership seeks to leverage the strengths of the two companies to develop first-in-class drugs to address unmet needs in neuropsychotic diseases. The successful outcomes from this collaboration will provide first-in-class treatment for cognitive dysfunction in schizophrenia, Rett syndrome which is an orphan indication in the autism spectrum disorder, and treatment resistant depression.
The collaboration covers multiple programs which are being enabled by Mnemosyne's expertise in drug discovery and NMDA receptor pharmacology and supported by Jubilant's translational center in Malvern, Pennsylvania, US, and by scientists from Jubilant's India based facilities. Under the terms of the alliance agreement, Mnemosyne will exclusively own all IP generated and shall be responsible for clinical development and commercialization.
Dr Subir Basak, president, Jubilant Biosys, said that, "Jubilant has always been a preferred partner for large pharma for their integrated discovery need and has worked with large and mid size pharma over the years but has had limited exposure in collaborating with innovative biotech companies like Mnemosyne. However, the nature of the pharmaceutical industry is changing and we have realized that a great deal of cutting edge research is actually been done in these small start-up companies. When Mnemosyne showed interest in Jubilant's integrated discovery capabilities, we realized that this collaboration would be a very good fit with our expertise in neuroscience, and would allow us to showcase our capabilities of the translational center in Malvern."
Focusing on biosimilars
June 2012 saw an important partnership between Dr. Reddy's and Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focusing on monoclonal antibodies (Mabs). Mr Karnvir Mundrey, director, Atharva Lifesciences Consulting believes, that, "Biosimilars are next big thing for India after generics. Merck Serono's strength in developing, manufacturing and commercialization gives it an edge over its counter parts and Dr. Reddy's banks on its global expertise in marketing generics and biosimilars.
Thus, it would be an obvious option for Merck Serono for a deal with Dr. Reddy's. Not to forget the cost savings for Merck Serono as phase I development is carried out by Dr. Reddy's. Also, to a fruitful extent, the agreement will be a mutual benefit for both the parties as R&D will be carried out on cost sharing basis, and commercialization will be done by both parties in the US and Dr. Reddy's will receive royalties. The deal will help Dr. Reddy's expand its presence in the biosimilars space in select emerging markets and enables participation globally."
Collaborations will not stop
These are some of the examples of economic globalization that can be witnessed in India. The nation has swiftly recognized that its strengths lie in generics, clinical research and vaccine space and the players of these spaces have swiftly moved to collaborate with some of the renowned names of the industry to diversify their footprints all over the world primarily in the US. In the near future, there can be numerous examples that can be quoted to stress upon the fact that collaboration is becoming the key to succeed in life sciences industry.